Table 3

Summary of evidence for demographic predictors of adherence to MTX

PredictorStudyNOutcomeUnadjusted ES (95% CI)/univariate analysesp ValueAdjusted ES (95% CI)p Value
Gender
Per cent of maleContreras-Yanez et al24*93Adherent (CQ ≥9) vs non-adherent (CQ ≤8)8 (17%) vs 5 (11.9%)0.55NPNP
Salt and Frazier29*108Adherent (MARS ≥39) vs non-adherent (MARS ≤38)23 (24%) vs 4 (32%)0.69NPNP
Male vs femalede Thurah et al26941Non-adherence (CMG)12.0 (10.5 to 13.5) vs 12.5 (11.4 to 13.5)NS
Being malede Thurah et al2785Non-adherence (CQR ≤25th centile) at BLPR 0.7 (0.2 to 1.7)NSPR 0.8 (0.3 to 2.0)NS
de Thurah et al2765Non-adherence (CQR ≤25th centile) at 9 moPR 0.4 (0.1 to 1.3)NSPR 0.3 (0.1 to 1.3)NS
de Klerk et al22*,‡127Per cent of adherence (MEMS)β 13.5 (NP)<0.050.38 (NP)<0.05
Age
Age in yearsSalt and Frazier29*108Adherent (MARS ≥39) vs non-adherent (MARS ≤38)52±14 vs 53±90.77OR 1.01 (0.94 to 1.08)0.8
Contreras-Yanez et al24*93Adherent (CQ ≥9) vs non-adherent (CQ ≤8)42.7±14.1 vs 38.9±13.40.18NPNP
Waimann et al30107Per cent of adherence (MEMS)r −0.07>0.20NPNP
>67 vs <55 years oldde Thurah et al26941Non-adherence (CMG)13.1 (11.6 to 14.6) vs 10.8 (9.3 to 12.3)<0.01Not definedSig
>55de Thurah et al2785Non-adherence (CQR ≤25th centile) at BL0.5 (0.2 to 1.1)NSPR 0.6 (0.2 to 1.6)NS
>55de Thurah et al2765Non-adherence (CQR ≤25th centile) at 9 moPR 0.9 (0.4 to 2.0)NSPR 0.7 (0.3 to 1.7)NS
Ethnicity
White vs non-whiteSalt and Frazier29*108Adherent (MARS ≥39) vs non-adherent (MARS ≤38)84 (86%) vs 5 (56%)0.04OR 10.1 (1.66 to 61.4)0.01
Hispanic vs white vs African-AmericanWaimann et al30107Per cent of adherence (MEMS)66±17 vs 64±20 vs 60±24NSNPNP
Being single/living alone
SingleContreras-Yanez et al24*93Adherent (CQ ≥9) vs non-adherent (CQ ≤8)23 (49%) vs 25 (54%)0.68NPNP
Salt and Frazier29*108Adherent (MARS ≥39) vs non-adherent (MARS ≤38)16 (16%) vs 2 (22%)0.74OR 1.44 (0.15 to 13.7)0.75
Widowed/separated vs marriedWaimann et al30107Per cent of adherence (MEMS)56±19 vs 72±16<0.01NPNP
Widowed/separated vs singleWaimann et al30107Per cent of adherence (MEMS)56±19 vs 69±18<0.01NPNP
Living alone vs not living aloneWaimann et al30107Per cent of adherence (MEMS)56±21 vs 66±19<0.05NPNP
Education
< High school vs ≥ high schoolWaimann et al30107Per cent of adherence (MEMS)67±19 vs 62±20NSNPNP
Years of educationContreras-Yanez et al24*93Adherent (CQ ≥9) vs non-adherent (CQ ≤8)10.1±4.2 vs 11.4±3.50.09NPNP
Salt and Frazier29*108Non-adherence (MARS ≤38)OR 1.09 (1.50 to 0.79)0.61NPNP
School >10 yearsde Thurah et al2785Non-adherence (CQR ≤25th centile) at BLPR 1.7 (0.7 to 3.8)NSPR 1.5 (0.5 to 4.1)NS
de Thurah et al2765Non-adherence (CQR ≤25th centile) at 9 moPR 1.3 (0.6 to 3.1)NSPR 1.0 (0.3 to 2.8)NS
Residence (rural vs urban)Salt and Frazier29*108Adherent (MARS ≥39) vs non-adherent (MARS ≤38)55 (51%) vs 48 (53%)0.18OR 7.52 (0.70 to 83.3)0.1
Employment status
Employed vs unemployedContreras-Yanez et al24*93Adherent (CQ ≥9) vs non-adherent (CQ ≤8)16 (34%) vs 15 (33%)1NPNP
EmployedSalt and Frazier29*108Adherent (MARS ≥39) vs non-adherent (MARS ≤38)27 (26%) vs 25 (26%)0.72OR 2.19 (21.3 to 0.21)0.52
Employed vs unemployedWaimann et al30104Per cent of adherence (MEMS)64±15 vs 63±14NSNPNP
Income <$20 000/year vs$20 000/yearWaimann et al3090Per cent of adherence (MEMS)62±19 vs 69±20NSNPNP
Low socioeconomic statusContreras-Yanez et al24*93Adherent (CQ ≥9) vs non-adherent (CQ ≤8)43 (92%) vs 40 (87%)0.52NPNP
Uninsured vs private vs medicaidWaimann et al30103Per cent of adherence (MEMS)65±15 vs 66±13 vs 64±19NSNPNP
English vs Spanish languageWaimann et al30107Per cent of adherence (MEMS)64±21 vs 65±19NSNPNP
  • *Studies judged low quality.

  • †MTX adherence.

  • ‡Includes RA, PMR and gout.

  • 9 mo, 9 months; BL, baseline; CMG, continuous measure of medication gaps; CQ, Compliance Questionnaire; ES, effect size; MEMS, Medication Electronic Monitoring System; CQR, Compliance Questionnaire-Rheumatology; MARS, Medication Adherence Revised Scale; MTX, methotrexate; NP, information not presented; NS, non-significant; PR, prevalence ratio; r, Pearson correlation coefficient; RA, rheumatoid arthritis; Sig, significant; β, regression coefficient.